Finasteride and dutasteride, both 5-alpha reductase inhibitors, are considered first-line
treatment for androgenetic hair loss in men and used increasingly in women. In each case …

Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary
tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a …

Background Because the optimal timing of the institution of antiandrogen therapy for
prostate cancer is controversial, we compared immediate and delayed treatment in patients …

OBJECTIVES: Six randomized clinical trials have compared at least 1 year of 5 mg
finasteride to placebo in the treatment of clinical benign prostatic hyperplasia (BPH). The …

Context: Dutasteride and finasteride are 5α-reductase inhibitors (5ARIs) that dramatically
reduce serum levels of dihydrotestosterone (DHT). Objective: Because androgens are …

OBJECTIVE: To evaluate the efficacy and safety of 2 years' treatment of moderate benign
prostatic hyperplasia (BPH) with finasteride. DESIGN: Double-blind, parallel-group, placebo …

Abstract Background The Prostate Cancer Prevention Trial (PCPT) reported a decreased
incidence of prostate cancer overall but an increase in the incidence of high-grade prostate …

Importance There is evidence that 5α-reductase inhibitors (5-ARIs), a standard treatment of
benign prostate hyperplasia, are associated with a decrease in the incidence of prostate …

Objective: The development of the human benign prostatic hyperplasia clearly requires a
combination of testicular androgens and aging. Although the role of androgens as the …

Benign prostatic hyperplasia is a nonmalignant enlargement of the prostate that is due to
excessive cellular growth of both the glandular and the stromal elements of the gland. The …